190 related articles for article (PubMed ID: 34233727)
1. Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial.
Jung SY; Koh JH; Kim KJ; Park YW; Yang HI; Choi SJ; Lee J; Choi CB; Kim WU
Arthritis Res Ther; 2021 Jul; 23(1):182. PubMed ID: 34233727
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and cost-effectiveness of triple therapy in preventing relapse in rheumatoid arthritis: A randomized controlled trial (ESCoRT study).
Zhao J; Zhou W; Wu Y; Yan X; Yang L; Zhang Z
Chin Med J (Engl); 2022 Sep; 135(18):2200-2209. PubMed ID: 36525606
[TBL] [Abstract][Full Text] [Related]
3. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
4. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study).
Zhao J; Zhou W; Wu Y; Ji P; Yang L; Yan X; Zhang Z
BMC Med Inform Decis Mak; 2021 Mar; 21(1):83. PubMed ID: 33663487
[TBL] [Abstract][Full Text] [Related]
5. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
6. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
7. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A
Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of low disease activity and remission with etanercept-disease-modifying antirheumatic drug (DMARD) combination therapy compared with treatment with DMARDs alone in Latin American patients with active rheumatoid arthritis: Subset analysis of a randomized trial.
Zerbini CAF; Abud-Mendoza C; Mendez-Patarroyo P; De Angelo Andrade M; Pedersen R; Vlahos B; Borlenghi CE
Medicine (Baltimore); 2018 Sep; 97(36):e11989. PubMed ID: 30200078
[TBL] [Abstract][Full Text] [Related]
9. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.
Takahashi N; Fujibayashi T; Kida D; Hirano Y; Kato T; Kato D; Saito K; Kaneko A; Yabe Y; Takagi H; Oguchi T; Miyake H; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Takemoto T; Terabe K; Asai N; Yoshioka Y; Ishiguro N; Kojima T
Rheumatol Int; 2015 Oct; 35(10):1707-16. PubMed ID: 25991396
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.
Naniwa T; Iwagaitsu S; Kajiura M
Int J Rheum Dis; 2018 Mar; 21(3):673-687. PubMed ID: 29314738
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
[TBL] [Abstract][Full Text] [Related]
13. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Lexberg ÅS; Madland TM; Fremstad H; Høili CA; Bakland G; Spada C; Haukeland H; Hansen IM; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
Ann Rheum Dis; 2023 Nov; 82(11):1394-1403. PubMed ID: 37607809
[TBL] [Abstract][Full Text] [Related]
14. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor inhibitor due to clinical remission.
Naniwa T; Iwagaitsu S; Kajiura M
Mod Rheumatol; 2017 Jan; 27(1):29-34. PubMed ID: 27143107
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate.
Shin K; Baek HJ; Kang YM; Cha HS; Kang SW; Park SH; Jun JB; Lee YJ; Choi IA; Song YW
Int J Rheum Dis; 2019 Jun; 22(6):1115-1122. PubMed ID: 30861334
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate.
Lee WS; Lee SI; Lee MS; Kim SI; Lee SS; Yoo WH
Korean J Intern Med; 2016 Jul; 31(4):779-87. PubMed ID: 26961485
[TBL] [Abstract][Full Text] [Related]
18. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
19. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
[TBL] [Abstract][Full Text] [Related]
20. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.
Edwards CJ; Östör AJK; Naisbett-Groet B; Kiely P
Rheumatology (Oxford); 2018 Jan; 57(1):84-91. PubMed ID: 29155973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]